CAM
DGX icon

Claret Asset Management’s Quest Diagnostics DGX Stock Holding History

Claret Asset Management’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$225K Sell
1,061
-227
-18% -$44.6K 0.02% 384
2026
Q1 		$252K Hold
1,288
– – 0.03% 245
2025
Q4 		$223K Sell
1,288
-3
-0.2% -$546 0.03% 325
2025
Q3 		$246K Sell
1,291
-18
-1% -$3.19K 0.03% 267
2025
Q2 		$235K Buy
+1,309
New +$227K 0.03% 238
2025
Q1 		– Sell
-1,429
Closed -$235K – 204
2024
Q4 		$216K Buy
1,429
+10
+0.7% +$1.55K 0.03% 247
2024
Q3 		$220K Buy
+1,419
New +$212K 0.04% 253

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Claret Asset Management's DGX Position: Q2 2026 in Review

Claret Asset Management reduced its Quest Diagnostics (DGX) stake by 18% in Q2 2026, selling an estimated $44.6K and leaving 1,061 shares worth $225K. The position accounts for 0.02% of the portfolio, ranked #384.

Claret Asset Management first reported a position in DGX in Q3 2024 and has held it in 7 quarters since. The position peaked at $252K in Q1 2026. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Claret Asset Management held 1,061 shares of Quest Diagnostics worth $225K as of Q2 2026.
  • Claret Asset Management sold 227 Quest Diagnostics shares in Q2 2026, an estimated $44.6K.
  • Quest Diagnostics made up 0.02% of Claret Asset Management's portfolio in Q2 2026, its #384 holding.
  • Claret Asset Management first reported a position in Quest Diagnostics in Q3 2024 and has held it in 7 quarters since.
  • Claret Asset Management's Quest Diagnostics position peaked at $252K in Q1 2026.
  • 1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Claret Asset Management's 13F filing for Q2 2026, filed 27 Jul 2026.